Antithrombotic and Hemorrhagic Effects of DX-9065a, a Direct and Selective Factor Xa Inhibitor: Comparison with a Direct Thrombin Inhibitor and Antithrombin Ill-Dependent Anticoagulants

Yoshiyuki Morishima; Kiyoshi Tanabe; Yasuko Terada; Tsuyoshi Hara; Satoshi Kunitada

doi:10.1055/s-0038-1665413

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 78(05): 1366-1371
DOI: 10.1055/s-0038-1665413

Review Article

Schattauer GmbH Stuttgart

Antithrombotic and Hemorrhagic Effects of DX-9065a, a Direct and Selective Factor Xa Inhibitor: Comparison with a Direct Thrombin Inhibitor and Antithrombin Ill-Dependent Anticoagulants

Yoshiyuki Morishima

¹The New Product Research Laboratories III, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, Japan

,

Kiyoshi Tanabe

²New Product Research Laboratories II, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, Japan

,

Yasuko Terada

²New Product Research Laboratories II, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, Japan

,

Tsuyoshi Hara

²New Product Research Laboratories II, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, Japan

,

Satoshi Kunitada

²New Product Research Laboratories II, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, Japan

› Author Affiliations

Abstract

PDF Download

Summary

(+)-2S-2-[4-[[(3S)-l-acetimidoyl-3- pyrrolidinyl]oxy]phenyl]-3-[7-amidino-2-naphthyl]propanoic acid hydrochloride pentahydrate (DX- 9065a) is an antithrombin III (AT III)-independent and selective inhibitor of activated blood coagulation factor X (FXa). The aim of the present study was to compare the antithrombotic and hemorrhagic effects of DX-9065a with a direct thrombin inhibitor and AT Ill-dependent anticoagulants in rat models of thrombosis and bleeding.

Rats were administered intravenously DX-9065a (0.1-1 mg/kg/h), argatroban (0.1-1 mg/k/h), low molecular weight heparin (25-100 anti- XaU/kg/h), unfractionated heparin (25-100 anti-XaU/kg/h) or Orgaran (30-300 anti-XaU/kg/h) for 1 h. DX-9065a dose-dependently inhibited both thrombus formation and elevation in plasma thrombin-AT III complex (TAT) level in a copper wire-inserted arteriovenous (AV) shunt model in rats. The dose required for 50% inhibition of thrombus formation was 0.27 mg/kg/h. DX-9065a did not prolong transection bleeding time up to 7.78 mg/kg/h. Argatroban and AT Ill-dependent anticoagulants also inhibited both thrombus formation and TAT elevation, but prolonged bleeding time at a slightly higher dose than the effective dose. These results suggest that direct and selective inhibition of factor Xa by DX-9065a is preferable for the treatment of thrombosis in the aspect of lack of compromising primary hemostasis.

PDF (1238 kb)

References

References
1 Harker LA. New antithrombotic strategies for resistant thrombotic processes. J Clin Pharmacol 1994; 34: 3-16
2 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-throm-bus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-665
3 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012
4 Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci USA 1992; 89: 6040-6044
5 Kumada T, Abiko Y. Comparative study on heparin and a synthetic thrombin inhibitor No.805(MD-805) in experimental antithrombin III-deficient animals. Thromb Res 1981; 24: 285-288
6 Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18-27
7 Jang I-K, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-225
8 Morishita K, Wada M, Kumada T, Tanaka T, Tomikawa M, Iwamoto M. Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. Thromb Res 1991; 63: 373-384
9 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188
10 Bagdy D, Szabó G, Barabás É, Bajusz S. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis. Thromb Haemost 1992; 68: 125-129
11 Jackson CV, Crowe VG, Frank JD, Wilson HC, Coffman WJ, Utterback BG, Jakubowski JA, Smith GF. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenyl-alanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 1992; 261: 546-552
12 Knabb RM, Kettner CA, Timmermans PBMWM, Reilly TM. In vivo characterization of a new synthetic thrombin inhibitor. Thromb Haemost 1992; 67: 56-59
13 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
14 Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992; 22: 58-65
15 Meuleman DG, Hobbelen PMJ, van DedemG, Moelker HCT. A novel antithrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal models. Thromb Res 1982; 27: 353-363
16 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions:The influence of the method of preparation. Thromb Res 1984; 35: 613-625
17 Hobbelen PMJ, Vogel GMT, Princen AWM, Meuleman DG. Benefit (anti-thrombotic)/risk (bleeding) ratio of various heparin(oid)s in experimental models in rats. Thromb Haemost 1985; 54: 32
18 Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991; 84: 1741-1748
19 Schaffer LW, Davidson JT, Vlasuk GP, Dunwiddie CT, Siegl PKS. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler Thromb 1992; 12: 879-885
20 Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-262
21 Fioravanti C, Burkholder D, Francis B, Siegl PKS, Gibson RE. Anti-thrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thromb Res 1993; 71: 317-324
22 Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kuma-bashiri I, Morishita E, Ikeda T, Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 1994; 72: 393-396
23 Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, prevents thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-639
24 Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 485-491
25 Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-319
26 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
27 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin anti-thrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1968; 59: 101-106
28 Finney D. Probit analysis. Cambridge University Press; London: 1952
29 Fenton JW. Thrombin. Ann NY Acad Sci 1986; 485: 5-15
30 Gruber A, Griffin JH, Hawker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639-642
31 Gruber A, Hanson SR, Kelly AB, Yan BS, Bang N, Griffin JH, Harker LA. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 1982; 82: 578-585
32 Ofosu FA, Fernandez F, Anvari N, Caranobe C, Dol F, Cadroy Y, Petitou M, Mardiguian J, Sié P, Boneu B. Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits. Thromb Haemost 1988; 60: 188-192
33 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
34 Cadroy Y, Hanson SR, Harker LA. Antithrombotic effects of synthetic penta-saccharide with high affinity for plasma antithrombin III in nonhuman primates. Thromb Haemost 1993; 70: 631-635
35 Majerus PW, Tollefson DM, Shuman MA. The interaction of platelets with thrombin. In Platelets in Biology and Pathology. Gordon JL. ed. North-Holland Publishing; Amsterdam: 1976. pp 241-260
36 Mills DCB, Macfarlene DE. Platelet receptors. In Platelets in Biology and Pathology. Gordon JL. ed. North-Holland Publishing; Amsterdam: 1976. pp 160-202